title: Bortezomib, thalidomide and dexamethasone versus bortezomib, cyclophosphamide and dexamethasone as induction therapy prior to ASCT in multiple myeloma - response to Moreau et al.
authors.affiliation: Division of Haematology and Bone marrow Transplantation, Sheba Medical Centre, Tel-Hashomer, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. merav.leiba@sheba.health.gov.il.
authors.forename: Merav
authors.initials: M
authors.lastname: Leiba
authors.forename: Abraham
authors.initials: A
authors.lastname: Avigdor
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*
keywords: bortezomib, cyclophosphamide and dexamethasone; bortezomib, thalidomide and dexamethasone; induction therapy; multiple myeloma